OBJECTIVES: Clinical practice guidelines recommend at least annual testing of estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (uACR) for patients with chronic kidney ...

Credit: Shutterstock Using both the ASCVD score and the KDIGO risk categories to estimate the risk for cardiovascular events could better inform preventive treatment decisions. Clinicians can enhance ...

Please provide your email address to receive an email when new articles are posted on . In a 5-year period, 18.9% of patients with chronic kidney disease and type 2 diabetes progressed from moderate ...

Chronic kidney disease (CKD) is a major risk factor for cardiovascular events, and controlling blood pressure (BP) is essential for reducing this risk in CKD patients. Although office BP is the ...

An Australian medical technology company, Proteomics International, has published a study demonstrating a new blood test significantly outperforms conventional tests in identifying the risk of ...

CKD is a global health problem affecting approximately 840 million people 1. New therapies to slow the progression of CKD have become available and are recommended by clinical practice guidelines 2.

A literature search was carried out for this briefing in accordance with the interim process and methods statement. This briefing includes the most relevant or best available published evidence ...

In a recent study published in Kidney International Reports, researchers investigated the effects of semaglutide (administered once weekly) on kidney disease outcomes and changes in KDIGO (short for ...

Residual risk for CKD persists despite healthy lifestyles and treatment of risk factors, according to a KDIGO controversies conference report. Kidney Disease: Improving Global Outcomes (KDIGO) ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...